The American Society for Pharmacy Law (ASPL) is an organization of attorneys, pharmacists, pharmacist-attorneys and students of pharmacy or law who are interested in the law as it applies to pharmacy, pharmacists, wholesalers, manufacturers, state and federal government and other interested parties.

ASPL is a non-profit which encourages diversity & inclusion with the Society, regardless of differing backgrounds, perspectives, experiences, orientations, origins, and practice settings. The Society embraces participation and diversity as it leads to advancing our purpose: 

  • Furthering knowledge in the law related to pharmacists, pharmacies, the provision of pharmaceutical care, the manufacturing and distribution of drugs, and other food, drug, and medical device policy issues;
  • Communicating accurate legal educational information; and
  • Providing educational opportunities for pharmacists, attorneys, and others who are interested in pharmacy law

Latest News

December 5, 2023


The owners of Purdue Pharma, L.P., have crafted a settlement agreement to conclude thousands of lawsuits in a wide variety of jurisdictions across the country. The U.S. Supreme Court will hear arguments regarding one facet of that complex settlement agreement – a provision that would shed members of the Sackler family, owners of the firm, from future lawsuits. In exchange the family would earmark up to $6B for the settlement and would relinquish control of the company.

The Supreme Court has scheduled arguments for December 4 and has framed the issue this way: Whether the Bankruptcy Code authorizes a court to approve, as part of a plan of reorganization under Chapter 11 of the Bankruptcy Code, a release that extinguishes claims held by non-debtors against non-debtor third parties, without the claimants’ consent.

[Ovalle D, Barnes R. As High Court Weighs Purdue Bankruptcy, Opioid Settlement Divides Victims. Washington Post, December 3, 2023; Harrington v. Purdue Pharm, L.P., U.S.S.C. 23-124, Cert Granted August 10, 2023 to review 69 F.4th 45 (2nd Cir, 2023).]